The malignancy of thyroid nodules is generally reported as a result of ultrasound, and pathology reports are mostly directly reported as to which staging of cancer. The first thing we do is to further refine the puncture biopsy examination to further determine the malignant nodule staging through pathological examination. The treatment regression of thyroid cancer mainly depends on the staging. There are 4 common pathological classifications: (1) papillary adenocarcinoma, accounting for 60% to 80%; (2) follicular adenocarcinoma, accounting for 10% to 28%. It is called differentiated thyroid cancer because it originates from the follicular epithelium of the thyroid gland and has a good prognosis after treatment; (3) medullary carcinoma, which originates from the parafollicular cells or c cells of the thyroid gland, accounting for 3% to 10%; (4) undifferentiated carcinoma, accounting for 3% to 8%. Among thyroid cancers, more than 90% are differentiated thyroid cancers.
Undifferentiated carcinoma progresses rapidly, with rapid onset of hoarseness and dyspnea. The prognosis is poor, with most dying within 1 year. 5-year survival rate is only 5-15%. The 5-year survival rate is only 5-15%. If the disease is undifferentiated, surgery should be followed by drug therapy.
However, most thyroid cancers are differentiated and have a better prognosis. Surgical resection and lymph node dissection are required.